Included in the formulation
АТХ:A.02.B.X Other antiulcer drugs
Pharmacodynamics:Oppression of proteolysis.
Pharmacokinetics:Not studied.
Indications:- Stomach ulcer and duodenal ulcer;
- Pancreatitis;
- Pancreatic necrosis;
- Obliterating arterial diseases;
- Alcoholism.
V.F10-F19.F10.1 Mental and behavioral disorders caused by alcohol use - harmful use
IX.I70-I79.I73.0 Raynaud's syndrome
IX.I70-I79.I73.1 Obliterating thromboangitis [Berger's disease]
IX.I70-I79.I79.2 * Peripheral angiopathy in diseases classified elsewhere
XI.K20-K31.K25 Stomach ulcer
XI.K20-K31.K26 Duodenal ulcer
XI.K80-K87.K85 Acute pancreatitis
XI.K80-K87.K86.1 Other chronic pancreatitis
Contraindications:Hypersensitivity, arterial hypotension, acute infectious processes, pregnancy.
Pregnancy and lactation:Adequate and well-controlled studies in humans and animals have not been conducted. Do not apply! There is no information on the penetration into breast milk. Do not apply! Category of recommendations FDA is not defined.
Dosing and Administration:With peptic ulcer drug is administered intramuscularly or intravenously. Single dose - 1-2 mg; the highest daily dose is 5 mg. The duration of treatment is usually 3-4 weeks. In / m injected, previously dissolved in 1 ml of 0.9% sodium chloride solution, 2 times / day. For intravenous administration, the drug is dissolved in 5-10 ml of 0.9% sodium chloride solution. In / in enter 1 time / sut.
For acute pancreatitis, I / 2 mg, then 5 mg 1-2 times / day. The course of treatment is 4-6 days.
With pancreatic necrosis - 5 mg 3-4 times / day (after 6-8 hours). The course of treatment is 2-6 days.
Injectable solutions are prepared immediately prior to administration.
Side effects:Decrease in blood pressure, allergic reactions.
Overdose:Not described.
Treatment is symptomatic.
Interaction:Not described.
Special instructions:Long-term efficacy and safety of use have not been studied. The expediency of use is not determined by large-scale clinical studies.
A substance of peptide nature, a synthetic hexapeptide, an analog of leucine-enkephalin. Suppresses proteolysis and promotes the healing of stomach and duodenal ulcers, has an antihypertensive effect.
It is not represented in US and UK Pharmacopoeias.